Related Experiment Video

Updated: Jun 24, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Autonomic dysfunction in chronic liver disease

James Frith1, Julia L Newton

  • 1Biomedical Research Centre in Ageing-Liver theme & Institute of Cellular Medicine, Newcastle University, Newcastle, UK. julia.newton@nuth.nhs.uk

Liver International : Official Journal of the International Association for the Study of the Liver
|March 28, 2009
PubMed

Insights

Autonomic dysfunction (AD) significantly impacts patients with chronic liver disease (CLD), worsening symptoms and increasing mortality risk. Early recognition and management of AD in CLD patients are crucial for improving outcomes.

Area of Science:

  • Hepatology
  • Autonomic Neuroscience
  • Clinical Medicine

Background:

  • Autonomic dysfunction (AD) is a frequent complication in chronic liver disease (CLD).
  • The pathophysiology of AD in CLD remains incompletely understood.
  • AD presents significant symptomatic burden and impacts patient quality of life.

Purpose of the Study:

  • To provide a practical clinical guide on autonomic dysfunction in chronic liver disease.
  • To detail common presentations, consequences, and management strategies for AD in CLD patients.

Main Methods:

  • Literature review of existing studies on autonomic dysfunction in liver disease.
  • Clinical observations and case studies synthesis.
  • Guideline development for clinicians.

Main Results:

  • AD is prevalent across all CLD etiologies, particularly in those awaiting liver transplantation.
  • Specific liver disease factors complicate the presentation and management of AD.
  • Increased morbidity and mortality are associated with AD in CLD patients.

Conclusions:

  • Recognition, investigation, and management of AD are vital in CLD patients.
  • A structured approach to AD diagnosis and treatment can mitigate adverse outcomes.
  • Further research into AD pathophysiology in CLD is warranted.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...